| Schedule of segment reporting information |
The following table presents information by reportable operating segment for the three and nine months ended September 30, 2019 and 2018 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
Nine months ended September 30, |
|
2019 |
|
2018 |
|
2019 |
|
2018 |
Consumer Products |
|
|
|
|
|
|
|
Product sales, net |
$ |
12,603 |
|
|
$ |
13,601 |
|
|
$ |
44,368 |
|
|
$ |
34,020 |
|
Gross profit |
8,428 |
|
|
9,946 |
|
|
30,938 |
|
|
24,567 |
|
Research and development expense |
437 |
|
|
171 |
|
|
1,815 |
|
|
363 |
|
Selling, general and administrative expense |
8,646 |
|
|
5,870 |
|
|
36,230 |
|
|
15,916 |
|
Operating income (loss) |
$ |
(655 |
) |
|
$ |
3,905 |
|
|
$ |
(7,107 |
) |
|
$ |
8,288 |
|
|
|
|
|
|
|
|
|
Specialty Pharmaceutical |
|
|
|
|
|
|
|
Product sales, net |
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Gross profit |
— |
|
|
— |
|
|
— |
|
|
— |
|
Research and development expense |
1,107 |
|
|
359 |
|
|
2,759 |
|
|
762 |
|
Selling, general and administrative expense |
11 |
|
|
20 |
|
|
31 |
|
|
36 |
|
Operating loss |
$ |
(1,118 |
) |
|
$ |
(379 |
) |
|
$ |
(2,790 |
) |
|
$ |
(798 |
) |
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
|
|
Product sales, net |
$ |
12,603 |
|
|
$ |
13,601 |
|
|
$ |
44,368 |
|
|
$ |
34,020 |
|
Gross profit |
8,428 |
|
|
9,946 |
|
|
30,938 |
|
|
24,567 |
|
Research and development expense |
1,544 |
|
|
530 |
|
|
4,574 |
|
|
1,125 |
|
Selling, general and administrative expense |
8,657 |
|
|
5,890 |
|
|
36,261 |
|
|
15,952 |
|
Operating income (loss) |
$ |
(1,773 |
) |
|
$ |
3,526 |
|
|
$ |
(9,897 |
) |
|
$ |
7,490 |
|
|